Literature DB >> 16801452

Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection.

Anthony Cacciapuoti1, Judith Halpern, Cara Mendrick, Christine Norris, Reena Patel, David Loebenberg.   

Abstract

The interaction of posaconazole and caspofungin was evaluated in concomitant treatment of Aspergillus fumigatus (two strains) or A. flavus (one strain) systemic infections in immunocompetent mice. Survival curves for mice treated with the combinations were compared statistically with those for mice treated with the component monotherapies. No antagonism was observed.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16801452      PMCID： PMC1489801          DOI： 10.1128/AAC.00829-05

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

Review 1.  Combinations of antifungal agents in therapy--what value are they?

Authors:  Manuel Cuenca-Estrella
Journal:  J Antimicrob Chemother       Date:  2004-09-16       Impact factor: 5.790

2.  Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America.

Authors:  D A Stevens; V L Kan; M A Judson; V A Morrison; S Dummer; D W Denning; J E Bennett; T J Walsh; T F Patterson; G A Pankey
Journal:  Clin Infect Dis       Date:  2000-04-20       Impact factor: 9.079

3.  Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys.

Authors:  A A Nomeir; P Kumari; M J Hilbert; S Gupta; D Loebenberg; A Cacciapuoti; R Hare; G H Miller; C C Lin; M N Cayen
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

4.  Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice.

Authors:  G K Abruzzo; C J Gill; A M Flattery; L Kong; C Leighton; J G Smith; V B Pikounis; K Bartizal; H Rosen
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

5.  Interactions between triazoles and amphotericin B against Cryptococcus neoformans.

Authors:  F Barchiesi; A M Schimizzi; F Caselli; A Novelli; S Fallani; D Giannini; D Arzeni; S Di Cesare; L F Di Francesco; M Fortuna; A Giacometti; F Carle; T Mazzei; G Scalise
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

Review 6.  Nosocomial aspergillosis is waterborne.

Authors:  E J Anaissie; S F Costa
Journal:  Clin Infect Dis       Date:  2001-09-24       Impact factor: 9.079

7.  In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida.

Authors:  A Cacciapuoti; D Loebenberg; E Corcoran; F Menzel; E L Moss; C Norris; M Michalski; K Raynor; J Halpern; C Mendrick; B Arnold; B Antonacci; R Parmegiani; T Yarosh-Tomaine; G H Miller; R S Hare
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

8.  Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group.

Authors:  T F Patterson; W R Kirkpatrick; M White; J W Hiemenz; J R Wingard; B Dupont; M G Rinaldi; D A Stevens; J R Graybill
Journal:  Medicine (Baltimore)       Date:  2000-07       Impact factor: 1.889

9.  Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus.

Authors:  Elias K Manavathu; George J Alangaden; Pranatharthi H Chandrasekar
Journal:  J Antimicrob Chemother       Date:  2003-04-25       Impact factor: 5.790

Review 10.  Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001.

Authors:  William J Steinbach; David A Stevens; David W Denning
Journal:  Clin Infect Dis       Date:  2003-10-01       Impact factor: 9.079
View more
  11 in total

1.  Role of innate immune receptors in paradoxical caspofungin activity in vivo in preclinical aspergillosis.

Authors:  Silvia Moretti; Silvia Bozza; Carmen D'Angelo; Andrea Casagrande; Maria Agnese Della Fazia; Lucia Pitzurra; Luigina Romani; Franco Aversa
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

2.  Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview.

Authors:  Hans-Peter Lipp
Journal:  Br J Clin Pharmacol       Date:  2010-10       Impact factor: 4.335

3.  Synergistic effect of posaconazole and caspofungin against clinical zygomycetes.

Authors:  María Guembe; Jesús Guinea; Teresa Peláez; Marta Torres-Narbona; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

Review 4.  Pharmacokinetic/pharmacodynamic profile of posaconazole.

Authors:  Yanjun Li; Ursula Theuretzbacher; Cornelius J Clancy; M Hong Nguyen; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

5.  The strength of synergistic interaction between posaconazole and caspofungin depends on the underlying azole resistance mechanism of Aspergillus fumigatus.

Authors:  Eleftheria Mavridou; Joseph Meletiadis; Antony Rijs; Johan W Mouton; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

6.  Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species.

Authors:  Charalampos Antachopoulos; Joseph Meletiadis; Tin Sein; Emmanuel Roilides; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2006-12-04       Impact factor: 5.191

7.  Differences in efficacy and cytokine profiles following echinocandin or liposomal amphotericin B monotherapy or combination therapy for murine pulmonary or systemic Aspergillus flavus infections.

Authors:  J A Olson; J Schwartz; D Hahka; A George; R T Proffitt; J P Adler-Moore
Journal:  Antimicrob Agents Chemother       Date:  2011-10-03       Impact factor: 5.191

8.  Posaconazole: A new agent for the prevention and management of severe, refractory or invasive fungal infections.

Authors:  Andrea V Page; W Conrad Liles
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-07       Impact factor: 2.471

9.  Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia.

Authors:  Charalampos Antachopoulos; Joseph Meletiadis; Tin Sein; Emmanuel Roilides; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2007-10-15       Impact factor: 5.191

10.  Posaconazole exhibits in vitro and in vivo synergistic antifungal activity with caspofungin or FK506 against Candida albicans.

Authors:  Ying-Lien Chen; Virginia N Lehman; Anna F Averette; John R Perfect; Joseph Heitman
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.